BCG therapy is associated with a high frequency of side effects in NMIBC; however, when used in sequential combination with ...

A recent study finds that sequential gemcitabine/docetaxel treatment offers better outcomes than additional BCG therapy for ...

Sanofi, GlaxoSmithKline, Abbott Biologicals, Bilthoven Biologicals, and Bharat Biotech International Lead the Global CompetitionDublin, Jan. 27, 2025 (GLOBE NEWSWIRE) -- The "BCG Vaccine Global Market ...

Neal Shore and Mark Tyson discuss advances in non-muscle invasive bladder cancer treatments, particularly for BCG unresponsive patients. They delve into the approval and data on nadofaragene ...

The high recurrence rate and the unpredictability of the progression pattern of bladder cancer have led to the widespread use of intravesical therapy as a supplement to TUR. Superficial bladder ...

Multicenter Analysis of Oncological Outcomes and Risk Dynamics EAU 2024: Subsequent Therapies After Intravesical BCG in Patients with Bladder Cancer: Analysis of Real-World Treatment Patterns EAU 2024 ...

The submission of this innovative intravesical drug releasing system is supported by data from the Phase 2b ... In December 2023, the FDA granted Breakthrough Therapy Designation (BTD) to TAR-200 for ...

However, the Merck and ImmunityBio drugs utilize a different mechanism of action — IBRX’s Anktiva is an IL-15 antibody drug, approved for intravesical use in combination with the BCG vaccine.

India is emerging as a leader in artificial intelligence (AI) investment and adoption, according to the latest AI Radarton Consulting Group (BCG) report from Bos. This report reveals that 80% of ...

The filing seeks approval for the treatment of patients with Bacillus Calmette-Guérin (BCG)-unresponsive high-risk non-muscle-invasive bladder cancer (HR-NMIBC) with carcinoma in situ (CIS), with or ...

ImmunityBio aims to expand Anktiva's approval for BCG-unresponsive NMIBC with papillary tumors, potentially reducing radical cystectomy rates. The QUILT-3.032 trial demonstrated promising disease-free ...

If patient with CIS do not have a complete response to treatment after a second induction course of ANKTIVA with BCG, reconsider cystectomy. DOSAGE AND ADMINISTRATION: For Intravesical Use Only. Do ...